Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

STRATA Skin Sciences (SSKN) Cash from Financing Activities (2016 - 2025)

STRATA Skin Sciences' Cash from Financing Activities history spans 13 years, with the latest figure at $2.2 million for Q3 2025.

  • For Q3 2025, Cash from Financing Activities rose 12.82% year-over-year to $2.2 million; the TTM value through Sep 2025 reached $2.2 million, up 13.87%, while the annual FY2024 figure was $1.9 million, 71.94% down from the prior year.
  • Cash from Financing Activities for Q3 2025 was $2.2 million at STRATA Skin Sciences, up from $1.9 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $7.0 million in Q2 2023 and bottomed at -$500000.0 in Q4 2022.
  • The 5-year median for Cash from Financing Activities is $92000.0 (2021), against an average of $1.5 million.
  • The largest annual shift saw Cash from Financing Activities skyrocketed 1968.27% in 2024 before it increased 12.82% in 2025.
  • A 5-year view of Cash from Financing Activities shows it stood at $92000.0 in 2021, then tumbled by 643.48% to -$500000.0 in 2022, then skyrocketed by 79.2% to -$104000.0 in 2023, then surged by 1968.27% to $1.9 million in 2024, then increased by 12.82% to $2.2 million in 2025.
  • Per Business Quant, the three most recent readings for SSKN's Cash from Financing Activities are $2.2 million (Q3 2025), $1.9 million (Q3 2024), and -$18000.0 (Q1 2024).